Abstract 1741P
Background
Little research has been made on real-world clinical scenarios of potential ethical relevance in specific cancers, including sarcomas.
Methods
Our sarcoma multidisciplinary tumor board (MTB) discusses all cases of adult patients with soft tissue sarcomas, bone sarcomas and GIST selected by the clinical oncologist in charge as deserving a multidisciplinary discussion. Over a 1-yr interval, all discussed cases were filtered by a group of senior and junior experts in bioethics and sarcomas in order to highlight those of potential ethical concern, i.e. whenever a problematic conflict could be envisaged between the ethical principles of beneficence, non-maleficence, autonomy and justice. These cases were retrospectively reviewed, and an attempt was made to group them into distinct ethical scenarios.
Results
From January to December 2023, 327 sarcoma cases were discussed by our MTB. Forty-one cases (12%) were prospectively or retrospectively selected as carrying possible ethical relevance. Among them, the following clinical scenarios were identified (total >100% since scenarios are not mutually exclusive): 1. ethically-relevant uncertainty about a diagnostic/treatment option (46%); 2. best treatment option at a high-risk of complications of problematic acceptance (5%); 3. controversial futility (17%); 4. problematic trade-off between quality and quantity of life (17%); 5. problematic management of patient dissent (15%); 6. clinical disagreement of potential ethical concern (10%); 7. problematic communication of all clinical implications to the individual patient (15%). 8. controversial enrolment of an eligible patient in a clinical trial or trial requirements of ethical concern in the individual patient (2%); 9. best clinical option conflicting with social/economical constraints (0.3%); 10. bedside rationing, or perception of implicit rationing of scarce resources (2%).
Conclusions
A non-negligible incidence of ethically-relevant clinical cases was observed. Sarcoma centres should be aware of specific ethical implications possibly affecting their everyday practice. Paradigmatic clinical cases for each of the ten clinical scenarios proposed herein will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1740P - Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients failed with anthracyclines chemotherapy or monotherapy post-anlotinib progression: A multi-center, phase II trial
Presenter: Yuhong Zhou
Session: Poster session 06
1742P - Factors influencing awareness of patient associations in sarcoma: A multicentric cross-sectional study
Presenter: Pau Mascaró Baselga
Session: Poster session 06
1743P - A phase II study of fruquintinib in the 1L or 2L treatment of unresectable metastatic soft tissue sarcoma
Presenter: Zhiguo Luo
Session: Poster session 06
1745P - How to optimize the response with trabectedin in soft tissue sarcomas? Data from a high-volume center
Presenter: Sebastian Diaz
Session: Poster session 06
1746P - Real-world characterization of patients with advanced or metastatic dedifferentiated liposarcoma (DDLPS) in Japan in MASTER KEY project
Presenter: Kenji Tsuchihashi
Session: Poster session 06
1747P - Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study
Presenter: Evelyne Roets
Session: Poster session 06
1748P - A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)
Presenter: Xi Guo
Session: Poster session 06
1749P - Vertebral MRI in the screening for bone metastasis in myxoid liposarcoma: Is it justified?
Presenter: Tania Moussa
Session: Poster session 06
1750P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Gale Rizzae Mercado Alcala
Session: Poster session 06
1751P - Clinical and survival data of 336 myxoid liposarcoma patients: The Gustave Roussy experience
Presenter: Tarek Assi
Session: Poster session 06